Skip to main content

Table 3 Ratio of C min and C max values to Historical Population Means by antiretroviral drug and dose

From: Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study

    Cmin Cmax
Antiretroviral agent   n n (%) >1.5 historical pop Mean Media ratio to historical population mean median ratio (IQR) p-value a n (%) >1.5 Historical pop mean Media ratio to historical population mean Median ratio ( IQR) p-value a
All   82 28 (34.1%) 1.21 (0.72-1.89) <.01 7 (8.5%) 0.82 (0.59-1.14) <.01
Atazanavir 400 QD 9 2 (22.2%) 0.78 (0.35-1.37) 0.71 0 (0.0%) 0.59 (0.31-0.94) 0.04
Atazanavir (boosted with ritonavir) 300 QD 18 4 (22.2%) 0.97 (0.77-1.42) 0.58 0 (0.0%) 0.66 (0.51-0.85) <.001
All Atazanavir   27 6 (22.2%) 0.95 (0.53-1.42) 0.76 0 (0.0%) 0.65 (0.44-0.87) <.0001
Lopinavir (boosted with ritonavir) 400 BID 16 3 (18.8%) 1.21 (0.79-1.40) 0.27 0 (0.0%) 0.86 (0.74-1.18) 0.32
Lopinavir (boosted with ritonavir) 800 QD 4 3 (75.0%) 3.79 (1.44-4.86) 0.25 0 (0.0%) 0.99 (0.63-1.26) 0.63
All Lopinavir   20 6 (30.0%) 1.22 (0.79-1.81) 0.11 0 (0.0%) 0.86 (0.72-1.21) 0.29
Efavirenz 600 DQ 16 6 (37.5%) 0.95 (0.67-1.95) 0.37 4 (25.0%) 0.79 (0.57-1.27) 0.63
Nevirapine 200 BID 11 5 (45.5%) 1.41 (0.91-1.93) 0.03 2 (18.2%) 0.96 (0.84-1.37) 0.46
Nevirapine 400 QD 8 5 (62.5%) 2.08 (0.90-2.53) 0.08 1 (12.5%) 0.96 (0.72-1.40) 0.95
All Nevirapine   19 10 (52.6%) 1.62 (0.91-2.32) <0.01 3 (15.8%) 0.96 (0.81-1.37) 0.47
  1. IQR, Interquartile range. a Sign rank test for a median ratio different than 1.